Compugen logo

Compugen Share Price (NASDAQ: CGEN)

$1.41

0.01

(0.71%)

Last updated on

Check the interactive Compugen Stock chart to analyse performance

Compugen stock performance

as on August 30, 2025 at 1:29 am IST

  • Today's Low:$1.39
    Today's High:$1.42

    Day's Volatility :2.11%

  • 52 Weeks Low:$1.13
    52 Weeks High:$2.66

    52 Weeks Volatility :57.52%

Compugen Stock Returns

PeriodCompugen LtdSector (Health Care)Index (Russel 2000)
3 Months
-6.67%
3.6%
0.0%
6 Months
-22.65%
-7.7%
0.0%
1 Year
-27.08%
-12.6%
0.0%
3 Years
21.74%
9.5%
-4.7%

Compugen Ltd Key Stats

Check Compugen key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$1.4
Open
$1.41
Today's High
$1.42
Today's Low
$1.39
Market Capitalization
$137.1M
Today's Volume
$298.1K
52 Week High
$2.66
52 Week Low
$1.13
Revenue TTM
$22.1M
EBITDA
$-19.3M
Earnings Per Share (EPS)
$-0.22
Profit Margin
-87.45%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-35.66%

Stock Returns calculator for Compugen Stock including INR - Dollar returns

The Compugen stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Compugen investment value today

Current value as on today

₹78,722

Returns

₹21,278

(-21.28%)

Returns from Compugen Stock

₹26,562 (-26.56%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Compugen Stock

64%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Compugen Stock from India on INDmoney has increased by 64% in the last 30 days, reflecting an upward trend in search activity.

Analyst Recommendation on Compugen Stock

Rating
Trend

Buy

    88%Buy

    11%Hold

    0%Sell

Based on 9 Wall street analysts offering stock ratings for Compugen(by analysts ranked 0 to 5 stars)

Compugen Share Price Target

What analysts predicted

Upside of 343.26%

Target:

$6.25

Current:

$1.41

Compugen share price target is $6.25, a slight Upside of 343.26% compared to current price of $1.41 as per analysts' prediction.

Compugen Stock Insights

  • Price Movement

    In the last 7 days, CGEN stock has moved down by -3.4%
  • CGEN vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 103.2%
  • CGEN vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 94.0%
  • Price to Sales

    ForCGEN every $1 of sales, investors are willing to pay $5.8, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Compugen Technicals Summary

Sell

Neutral

Buy

Compugen is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Compugen Ltd Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Compugen Ltd logo
-3.45%
-22.65%
-27.08%
21.74%
-91.81%
Regeneron Pharmaceuticals, Inc. logo
6.48%
-15.2%
-50.31%
-3.3%
-2.01%
Beone Medicines Ltd logo
1.77%
24.81%
62.78%
79.11%
29.69%
Vertex Pharmaceuticals Incorporated logo
-14.45%
-19.13%
-17.84%
34.68%
41.87%
Alnylam Pharmaceuticals, Inc. logo
13.79%
83.28%
75.87%
111.28%
242.25%

About Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Organization
Compugen
Employees
74
CEO
Dr. Anat Cohen-Dayag Ph.D.
Industry
Health Technology

Key Management of Compugen Ltd

NameTitle
Dr. Anat Cohen-Dayag Ph.D.
CEO, President & Director
Dr. Eran Ophir Ph.D.
Chief Scientific Officer
Dr. Zurit Levine Ph.D.
Senior Vice President of Strategic Collaborations
Dr. Pierre Ferre Ph.D.
Senior VP of Preclinical Development & Corporate Operations
Ms. Michelle Mahler M.D.
Chief Medical Officer
Ms. Yvonne Naughton
Head of Investor Relations & Corporate Communications
Mr. Eran Ben Dor
General Counsel & Corporate Secretary
Ms. Dorit Amitay
Vice President of Human Resources
Dr. Yaron Turpaz M.B.A., Ph.D.
Senior VP & Senior Advisor of Data and Informatics Solutions
Rivka Schwartz
Vice President Research and Discovery

Important FAQs about investing in CGEN Stock from India :

What is Compugen share price today?

Compugen share price today is $1.41 as on at the close of the market. Compugen share today touched a day high of $1.42 and a low of $1.39.

What is the 52 week high and 52 week low for Compugen share?

Compugen share touched a 52 week high of $2.66 and a 52 week low of $1.13. Compugen stock price today i.e. is closed at $1.41, lower by 46.99% versus the 52 week high.

How to invest in Compugen Stock (CGEN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Compugen on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Compugen Shares that will get you 1.0638 shares as per Compugen share price of $1.41 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Compugen Stock (CGEN) from India?

Indian investors can start investing in Compugen (CGEN) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Compugen stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Compugen share’s latest price of $1.41 as on August 30, 2025 at 1:29 am IST, you will get 7.0922 shares of Compugen. Learn more about fractional shares .

What are the returns that Compugen has given to Indian investors in the last 5 years?

Compugen stock has given -91.81% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?